Jubilant and Endo Pharmaceuticals announce Late Stage Discovery Milestone in Oncology Program
Bangalore, India, June 20, 2011 - Jubilant Biosys Ltd., Bengaluru based subsidiary of Jubilant Life Sciences Ltd., and Endo Pharmaceuticals (Nasdaq: ENDP), of Chadds Ford, Pa, U.S.A., announced today that they have achieved a late stage discovery milestone in their joint program focused on cancer.
This is the third milestone in the two-year-old, multi-target, oncology focused partnership and enables the collaboration to rapidly pursue a development candidate. Endo and Jubilant had entered into a multiyear, multi-target oncology focused partnership in 2009. As a part of the partnership, Jubilant delivers preclinical development candidates and has an option to participate in clinical development. Endo owns the development and commercial rights to the successful outcomes. However, Jubilant derives research funding, development milestones and sales royalties on successful commercialization
Commenting on this development, Sri Mosur, CEO & President, Global Drug Discovery & Development, Jubilant said: "We are pleased that we continue to enhance the portfolio outcomes for Endo Pharmaceuticals. It is an important achievement in our collaboration and demonstrates our scientist's commitment to Oncology research to deliver differentiated therapies to cancer patients worldwide. It will be our continued endeavor to support the collaboration in accelerating the development phase towards successful commercialization"
Sandeep Gupta, Sr. Vice President, Discovery and Early Development, Endo Pharmaceuticals commented: "We are pleased with the technical capabilities and productivity of the Jubilant team. They have done an outstanding job of designing novel molecules and to demonstrate preclinical proof of concept ahead of schedule. We look forward to nominating a development candidate in the near future."
Jubilant Biosys Ltd. (JBL) (www.jubilantbiosys.com) , a subsidiary of Jubilant Life Sciences Ltd., provides integrated drug discovery and development solutions to the global pharmaceutical industry. Jubilant Biosys has an integrated state of the art facility in Bangalore. The Center houses over 450 scientists specializing in multiple disciplines to include Discovery biology, medicinal chemistry, structural biology, pharmacology, toxicology, pharma chem, molecular modeling, crystallography and information technology supporting discovery efforts.
About Jubilant Life Sciences
Jubilant Life Sciences., headquartered at Noida, an integrated pharmaceutical industry player, is India‘s largest Custom Research and Manufacturing Services company (CRAMS) and a leading Drug Discovery and Development Solution Provider. The company has a presence across the pharmaceutical value chain for providing products and services such as proprietary products, exclusive synthesis, active pharmaceutical ingredients, contract manufacturing of sterile injectables & non-steriles products, radiopharmaceuticals, generic dosage forms, drug discovery services, medicinal chemistry services, clinical research services, and Health Care. The Company also manufactures Industrial and Performance products.
Disclaimer: Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Organosys may, from time to time, make additional written and oral forward looking statements, including statements contained in the Company’s filings with the regulatory bodies and its reports to shareholders. The Company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.